The pharmaceutical microneedle R&D company Theraject Asia Co., Ltd. (CEO Kyoung- Dong KIM) succeeded in developing a press-needle type syringe for the first time in Korea last year. This is an effort to secure the efficacy and convenience of microneedles for vaccines and active ingredient injections, a topic that has been widely discussed worldwide. The development has been patented in Korea and is pending an international patent.